Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 5Sarcoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Vulvar Neoplasms 1Recurrence 1Neuroendocrine Tumors 1Neoplasms 1Liver Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Disease 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1Advanced Adult Hepatocellular Carcinoma 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × tivozanib × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡